<div id="readability-page-1"><div><p><span></span></p><ul><li>Sunshine Biopharma Inc  is expected to  show a rise in quarterly revenue when it reports  results on November 3 (estimated) for the period ending September 30 2025</li><li>The Fort Lauderdale Florida-based  company is expected to report a 31.6% increase in revenue to $11.1 million from $8.44 million a year ago, according to the estimate from one analyst, based on LSEG data.</li><li>​LSEG's mean analyst estimate for Sunshine Biopharma Inc is for a loss of 13 cents per share. </li><li>The one available analyst rating on the shares is &#34;buy&#34;.  </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for Sunshine Biopharma Inc is $7.00, about 75% above its last closing price of $1.75</li></ul></div></div>

SBFM

<p>Sunshine Biopharma Inc is anticipated to report a quarterly revenue increase of 31.6%, reaching $11.1 million for the period ending September 30, 2025. However, the company is expected to incur a loss of 13 cents per share. The sole analyst rating for the stock is "buy," with a median 12-month price target of $7.00, significantly above its last closing price of $1.75.</p>

Sunshine Biopharma Inc expected to post a loss of 13 cents a share - Earnings Preview